Economic value of subcutaneous versus intravenous trastuzumab administration in the treatment of HER2-positive breast cancer: A systematic review

Tran Thi My Duyen; Nguyen Vu Lan Chi; Pham Tri Dung; Nguyen Thi Thu Thuy

doi:10.59294/HIUJS.VOL.7.2024.686

Từ khóa:

breast cancer, trastuzumab IV, SC, health economic, economic value

Tóm tắt

Introduction: Trastuzumab is the standard therapy for HER-positive breast cancer, traditionally administered intravenously (T-IV). The subcutaneous trastuzumab (T-SC), introduced in 2013, may may offer cost savings compared to T-IV. While previous studies have examined the economic value of T-SC, no quality assessment of these studies or a currency-standardized comparison across countries has been conducted. This study aimed to address these gaps by systematically reviewing and assessing the quality of economic evaluations comparing T-SC and T-IV. Methods: A systematic review of publications until May 31, 2021, was performed using databases like MEDLINE, Cochrane, and ScienceDirect, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. The quality of studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. All costs were adjusted to 2019 Euro using World Bank's consumer price index (CPI). Results: There were 14 out of 368 studies included in this systematic review. Most studies were conducted from a hospital perspective, showing cost savings of T-SC ranging from €52.6 to €29,617.3 per patient annually. Quality assessments based on the CHEERS checklist revealed that the number of compliant sections or items in the studies ranged from 11 to 19 out of 24. Conclusion: This systematic review demonstrated that T-SC might offer cost savings compared to T-IV in treating HER2-positive breast cancer. However, the limited number of studies and their methodological heterogeneity highlight the need for further comprehensive research to inform decision-makers on trastuzumab use.

Abstract

Introduction: Trastuzumab is the standard therapy for HER-positive breast cancer, traditionally administered intravenously (T-IV). The subcutaneous trastuzumab (T-SC), introduced in 2013, may may offer cost savings compared to T-IV. While previous studies have examined the economic value of T-SC, no quality assessment of these studies or a currency-standardized comparison across countries has been conducted. This study aimed to address these gaps by systematically reviewing and assessing the quality of economic evaluations comparing T-SC and T-IV. Methods: A systematic review of publications until May 31, 2021, was performed using databases like MEDLINE, Cochrane, and ScienceDirect, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. The quality of studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. All costs were adjusted to 2019 Euro using World Bank's consumer price index (CPI). Results: There were 14 out of 368 studies included in this systematic review. Most studies were conducted from a hospital perspective, showing cost savings of T-SC ranging from €52.6 to €29,617.3 per patient annually. Quality assessments based on the CHEERS checklist revealed that the number of compliant sections or items in the studies ranged from 11 to 19 out of 24. Conclusion: This systematic review demonstrated that T-SC might offer cost savings compared to T-IV in treating HER2-positive breast cancer. However, the limited number of studies and their methodological heterogeneity highlight the need for further comprehensive research to inform decision-makers on trastuzumab use.

Tài liệu tham khảo

[1] F. Bray, J. Ferlay, I. Soerjomataram,… and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," (in eng), CA Cancer J Clin, vol. 68, no. 6, pp. 394-424, Nov 2018.

DOI: https://doi.org/10.3322/caac.21492

[2] J. A. Freudenberg, Q. Wang,… and M. I. Greene, "The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies," (in eng), Exp Mol Pathol, vol. 87, no. 1, pp. 1-11, Aug 2009.

DOI: https://doi.org/10.1016/j.yexmp.2009.05.001

[3] N. Iqbal and N. Iqbal, "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications," (in eng), Mol Biol Int, vol. 2014, p. 852748, 2014.

DOI: https://doi.org/10.1155/2014/852748

[4] W. Jacot et al., "Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2- positive breast cancer with brain metastases," (in eng), Breast Cancer Res Treat, vol. 157, no. 2, pp. 307-318, Jun 2016.

DOI: https://doi.org/10.1007/s10549-016-3828-6

[5] M. Sawaki et al., "Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer," (in eng), Tumori, vol. 90, no. 1, pp. 40-3, Jan-Feb 2004.

DOI: https://doi.org/10.1177/030089160409000110

[6] I. E. Smith, "Efficacy and safety of Herceptin in women with metastatic breast cancer: Results from pivotal clinical studies," (in eng), Anticancer Drugs, vol. 12 Suppl 4, pp. S3-10, Dec 2001.

DOI: https://doi.org/10.1097/00001813-200112004-00002

[7] G. Ismael et al., "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open- label, multicentre, randomised trial," (in eng), Lancet Oncol, vol. 13, no. 9, pp. 869-78, Sep 2012.

DOI: https://doi.org/10.1016/S1470-2045(12)70329-7

[8] M. F. Haller, "Converting intravenous dosing to subcutaneous dosing: With recombinant human hyaluronidase," Pharmaceutical Technology, vol. 31, pp. 118-132, 10/01 2007.

[9] A. Inotai, T. Ágh, A. W. Karpenko, A. Zemplényi, and Z. Kaló, "Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries," (in eng), Expert Rev Pharmacoecon Outcomes Res, vol. 19, no. 2, pp. 105-113, Apr 2019.

DOI: https://doi.org/10.1080/14737167.2019.1554437

[10] The World Bank. Available: https://www.worldbank.org/

[11] D. Husereau et al., "Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-- explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force," (in eng), Value Health, vol. 16, no. 2, pp. 231- 50, Mar-Apr 2013.

DOI: https://doi.org/10.1016/j.jval.2013.02.002

[12] H. J. Rogers et al., "A systematic review of the quality and scope of economic evaluations in child oral health research," (in eng), BMC Oral Health, vol. 19, no. 1, p. 132, Jul 1 2019.

DOI: https://doi.org/10.1186/s12903-019-0825-2

[13] T. Vo and N. Nguyen-Hoang, "Assessing the Quality of Health Economic Evaluation Research by CHEERS Instrument: A Critical Literature Review in Laos, Cambodia, and Myanmar," Journal of Applied Pharmaceutical Science, vol. 7, pp. 222-228, 07/07 2017.

[14] R. T. North, V. J. Harvey,… and S. N. Ryan, "Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study," (in eng), Clinicoecon Outcomes Res, vol. 7, pp. 423-30, 2015.

DOI: https://doi.org/10.2147/CEOR.S85599

[15] R. Burcombe, S. L. Chan,… and P. Barrett-Lee, "Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer," 2013.

DOI: https://doi.org/10.4236/abcr.2013.24022

[16] A. Farolfi et al., "Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients," (in eng), Oncotarget, vol. 8, no. 46, pp. 81343- 81349, Oct 6 2017.

DOI: https://doi.org/10.18632/oncotarget.18527

[17] C. Ponzetti, M. Canciani,… and S. Walzer, "Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma andfor trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey," (in eng), Clinicoecon Outcomes Res, vol. 8, pp. 227-33, 2016.

DOI: https://doi.org/10.2147/CEOR.S97319

[18] E. Hedayati, L. Fracheboud,… and C. Linder Stragliotto, "Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden," (in eng), PLoS One, vol. 14, no. 2, p. e0211783, 2019.

DOI: https://doi.org/10.1371/journal.pone.0211783

[19] S. Olofsson, H. Norrlid,… and G. Ragnarson Tennvall, "Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting," (in eng), Breast, vol. 29, pp. 140- 6, Oct 2016.

DOI: https://doi.org/10.1016/j.breast.2016.07.008

[20] G. Lopez-Vivanco et al., "Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain," (in eng), Clin Transl Oncol, vol. 19, no. 12, pp. 1454-1461, Dec 2017.

DOI: https://doi.org/10.1007/s12094-017-1684-4

[21] W. A. A. Tjalma, T. Van den Mooter,… and K. Papadimitriou, "Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit," (in eng), Eur J Obstet Gynecol Reprod Biol, vol. 221, pp. 46-51, Feb 2018.

DOI: https://doi.org/10.1016/j.ejogrb.2017.12.006

[22] A. Lazaro Cebas et al., "Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use," (in eng), J buon, vol. 22, no. 2, pp. 334-339, Mar-Apr 2017.

[23] J. Olsen, K. F. Jensen,… and A. Knoop, "Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer," (in eng), J Comp Eff Res, vol. 7, no. 5, pp. 411-419, May 2018.

DOI: https://doi.org/10.2217/cer-2017-0048

[24] L. Rojas et al., "Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer," (in eng), PLoS One, vol. 15, no. 2, p. e0227961, 2020.

DOI: https://doi.org/10.1371/journal.pone.0227961

[25] G. L. O'Brien et al., "Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland," (in eng), Clin Breast Cancer, vol. 19, no. 3, pp. e440-e451, Jun 2019.

[26] M. G. Franken et al., "Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands," (in eng), Anticancer Drugs, vol. 29, no. 8, pp. 791-801, Sep 2018.

DOI: https://doi.org/10.1097/CAD.0000000000000648

[27] C. Blein et al., "A multi-center evaluation of clinical pathways cost and time using real-life data in patients treated for their breast cancer by Trastuzumab intravenous and subcutaneous in day sessions," British Journal of Cancer Research, vol. 1, no. 4, pp. 208-216, 2018.

DOI: https://doi.org/10.31488/bjcr.118

[28] G. L. O'Brien et al., "Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland," (in eng), Clinical breast cancer, vol. 19, no. 3, pp. e440-e451, 2019.

DOI: https://doi.org/10.1016/j.clbc.2019.01.011